Patents by Inventor Marianne Dorothy Sadar

Marianne Dorothy Sadar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS
    Publication number: 20250100986
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: October 17, 2024
    Publication date: March 27, 2025
    Inventors: Raymond John ANDERSEN, Marianne Dorothy SADAR, Kunzhong JIAN, Nasrin R. MAWJI, Jun WANG, Carmen Adriana BANUELOS, Yu-Chi YANG
  • HYDROXYPHENYL-ETHYNYL-PHENOL DERIVATIVES AS AR (ANDROGEN RECEPTOR) TRANSCRIPTIONAL ACTIVITY MODULATORS FOR USE IN THE TREATMENT OF I.A. PROSTATE CANCER
    Publication number: 20250009685
    Abstract: The present invention relates to compounds of formula (I) and their use for modulating the transcriptional activity of the androgen receptor and its splice variants for treating various indications including prostate cancer
    Type: Application
    Filed: September 22, 2022
    Publication date: January 9, 2025
    Inventors: Xavier SALVATELLA GIRALT, Antoni RIERA ESCALÉ, Marta FRIGOLÉ VIVAS, Carolina SÁNCHEZ ZARZALEJO, Alessandro RUFFONI, Francesc Xavier VERDAGUER ESPAULELLA, Marianne Dorothy SADAR, Carmen Adriana BANUELOS, Nasrin MAWJI
  • HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
    Publication number: 20240391883
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: August 1, 2024
    Publication date: November 28, 2024
    Inventors: Raymond John ANDERSEN, Javier Garcia FERNANDEZ, Kunzhong JIAN, Marianne Dorothy SADAR, Nasrin R. MAWJI, Carmen Adriana BANUELOS
  • Pharmaceutical compositions and combinations comprising inhibitors of the androgen receptor and uses thereof
    Patent number: 12109179
    Abstract: The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: October 8, 2024
    Assignees: ESSA PHARMA INC., THE UNIVERSITY OF BRITISH COLUMBIA, PROVINCIAL HEALTH SERVICES AUTHORITY
    Inventors: Peter Virsik, Han-Jie Zhou, Marianne Dorothy Sadar, Raymond John Andersen, Kunzhong Jian, Daniel Andrew Golec
  • Bisphenol derivatives and their use as androgen receptor activity modulators
    Patent number: 11919874
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: March 5, 2024
    Assignees: The University of British Columbia, Provincial Health Services Authority
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Bisphenol ether derivatives and methods for using the same
    Patent number: 11779550
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: December 9, 2020
    Date of Patent: October 10, 2023
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond John Andersen, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20220380325
    Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.
    Type: Application
    Filed: June 30, 2021
    Publication date: December 1, 2022
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar
  • Androgen receptor modulators and methods for their use
    Patent number: 11485713
    Abstract: Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: November 1, 2022
    Assignees: ESSA Pharma, Inc., The University of British Columbia, Provincial Health Services Authority
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Daniel Andrew Golec
  • HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
    Publication number: 20220267283
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: April 26, 2022
    Publication date: August 25, 2022
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • PHARMACEUTICAL COMPOSITIONS AND COMBINATIONS COMPRISING INHIBITORS OF THE ANDROGEN RECEPTOR AND USES THEREOF
    Publication number: 20220218632
    Abstract: The present disclosure generally relates to pharmaceutical compositions and combinations comprising an androgen receptor N-terminal domain inhibitor or an inhibitor and a second therapeutically active agent, such as an CDK4/6 inhibitor, a Pin1 inhibitor (inhibitor of peptidyl-prolyl cis/trans isomerases), or an antiandrogen. In particular, the present disclosure relates to pharmaceutical compositions and combinations useful for treatment of various cancers, for example breast cancer and prostate cancer. Further, the present disclosure relates administering an androgen receptor N-terminal domain inhibitor in combination with radiation therapy for treatment of various cancers.
    Type: Application
    Filed: March 27, 2020
    Publication date: July 14, 2022
    Inventors: Peter Virsik, Han-Jie Zhou, Marianne Dorothy Sadar, Raymond John Andersen, Kunzhong Jain, Daniel Andrew Golec
  • Heterocyclic compounds for cancer imaging and treatment and methods for their use
    Patent number: 11345670
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: May 1, 2020
    Date of Patent: May 31, 2022
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS
    Publication number: 20210387957
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: August 17, 2021
    Publication date: December 16, 2021
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Bisphenol derivatives and their use as androgen receptor activity modulators
    Patent number: 11142508
    Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: October 12, 2021
    Assignees: The University of British Columbia, Provincial Health Services Authority
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • Androgen receptor modulators and methods for their use
    Patent number: 11059795
    Abstract: The present invention relates to compounds of formula (I)-(VI) and/or (A)-(H-I), or any subgenera thereof, or a pharmaceutically acceptable salt, tautomer or stereoisomer. The compounds of the present disclosure are useful in modulating androgen receptor activity and for treating cancer including prostate cancer.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: July 13, 2021
    Assignees: ESSA Pharma, Inc., The University of British Columbia, Provincial Health Services Authority
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar
  • ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE
    Publication number: 20210198213
    Abstract: Compounds having a structure of formula (I), (I-A), (Ia)-(Ie), (A)-(E), and (II) or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of disorders including prostate cancer are also provided.
    Type: Application
    Filed: May 24, 2019
    Publication date: July 1, 2021
    Inventors: Han-Jie Zhou, Peter Virsik, Raymond John Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Daniel Andrew Golec
  • BISPHENOL ETHER DERIVATIVES AND METHODS FOR USING THE SAME
    Publication number: 20210100757
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: December 9, 2020
    Publication date: April 8, 2021
    Inventors: Raymond John Andersen, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • HETEROCYCLIC COMPOUNDS FOR CANCER IMAGING AND TREATMENT AND METHODS FOR THEIR USE
    Publication number: 20200325106
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: May 1, 2020
    Publication date: October 15, 2020
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos
  • BISPHENOL DERIVATIVES AND THEIR USE AS ANDROGEN RECEPTOR ACTIVITY MODULATORS
    Publication number: 20200317628
    Abstract: Compounds having a structure of Formula I or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, and X, are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: April 14, 2020
    Publication date: October 8, 2020
    Inventors: Raymond J. Andersen, Marianne Dorothy Sadar, Kunzhong Jian, Nasrin R. Mawji, Jun Wang, Carmen Adriana Banuelos, Yu-Chi Yang
  • BISPHENOL ETHER DERIVATIVES AND METHODS FOR USING THE SAME
    Publication number: 20200206155
    Abstract: Compounds having a structure of Formula I, or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, L1, L2, L3, X, a, b, c, n, and m are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity and uses as therapeutics as well as methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Application
    Filed: October 1, 2019
    Publication date: July 2, 2020
    Inventors: Raymond John ANDERSEN, Kunzhong JIAN, Marianne Dorothy SADAR, Nasrin R. MAWJI, Carmen Adriana BANUELOS
  • Heterocyclic compounds for cancer imaging and treatment and methods for their use
    Patent number: 10654811
    Abstract: Compounds having a structure of Formula I: or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof, wherein R1, R2, R3, R11a, R11b, R11c, R11d, X, n1, n2, and n3 are as defined herein, are provided. Uses of such compounds for modulating androgen receptor activity, imaging diagnostics in cancer and therapeutics, and methods for treatment of subjects in need thereof, including prostate cancer are also provided.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: May 19, 2020
    Assignees: The University of British Columbia, British Columbia Cancer Agency Branch
    Inventors: Raymond John Andersen, Javier Garcia Fernandez, Kunzhong Jian, Marianne Dorothy Sadar, Nasrin R. Mawji, Carmen Adriana Banuelos